Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer

morningstar.com·Jul 10, 2026 · 8 h fa

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

medpagetoday.com·Jul 10, 2026 · 13 h fa

FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

morningstar.com·Jul 10, 2026 · 11 h fa

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

benzinga.com·Jul 10, 2026 · 8 h fa

Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)

fiercepharma.com·Jul 10, 2026 · 9 h fa

Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca